February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Rituxan (Rituximab): Uses in Cancer, Side Effects, Dosages, Expectations, and More
Feb 16, 2025, 07:50

Rituxan (Rituximab): Uses in Cancer, Side Effects, Dosages, Expectations, and More

Rituxan (rituximab) is a monoclonal antibody that targets the CD20 protein on B-cells, playing a pivotal role in oncology as a form of immunotherapy. Since its FDA approval on November 26, 1997, Rituxan has become integral in treating certain cancers, offering a targeted approach distinct from traditional chemotherapy.

How Does Rituxan Work?

Rituxan is not a chemotherapy drug. Instead, it is a chimeric monoclonal antibody that targets CD20, a surface antigen found on B cells. It works by depleting both normal and pathogenic B cells while preserving plasma cells and hematopoietic stem cells, as they do not express the CD20 antigen. Once Rituxan binds to CD20, it works in two ways by either enhancing the immune system, which can trigger processes that lead to the cancer cells’ death on its own, or directly destructing cells. The latter helps your body’s natural defenses recognize and destroy cancer cells.

What Cancers is Rituximab (Rituxan) Approved to Treat?

Rituxan is a prescription medication administered by a healthcare professional. It can be used alone or in combination with other treatments for cancerous conditions, including Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in adults, as well as mature B-cell non-Hodgkin’s lymphoma (NHL) and mature B-cell acute leukemia (B-AL) in children aged six months and older. Additionally, it is indicated for autoimmune disorders such as rheumatoid arthritis in adults, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), which are rare inflammatory conditions affecting blood vessels and tissues treated in both adults and children aged two years and older, and pemphigus vulgaris, a severe autoimmune disease causing blisters and skin breakdown, treated in adults.

Rituxan in Non-Hodgkin’s Lymphoma

Relapsed or Refractory, Low-Grade or Follicular NHL (used as a single agent). Previously Untreated Follicular NHL (used in combination with first-line chemotherapy. If patients achieve a complete or partial response, Rituxan may be continued as single-agent maintenance therapy). Non-Progressing (Including Stable Disease), Low-Grade NHL (used as a single agent after first-line CVP chemotherapy (Cyclophosphamide, Vincristine, Prednisone)). Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (used in combination with CHOP chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) or other anthracycline-based regimens).

In the AUGMENT trial, published by John P. Leonard et al. in The Lancet (2019), the combination of Rituxan and lenalidomide (Revlimid) demonstrated significant improvements in progression-free survival (PFS) compared to Rituxan alone in patients with relapsed or refractory indolent NHL. The median PFS was 39.4 months in the Rituxan plus lenalidomide group versus 14.1 months in the Rituxan plus placebo group (HR=0.46, P<0.001). 

Additionally, the RELEVANCE trial, published by Gilles Salles et al. in The Lancet (2017), evaluated Rituxan in combination with chemotherapy regimens in previously untreated follicular NHL patients. The study found that Rituxan combined with chemotherapy resulted in improved PFS compared to chemotherapy alone.

These findings underscore the efficacy of Rituxan in various treatment settings for CD20-positive, B-cell NHL, highlighting its role in improving progression-free survival across different patient populations.

Rituxan for Pediatric Patients (Aged 6 Months and Older)

Rituxan is indicated for the treatment of advanced-stage, CD20-positive B-cell malignancies in children, including Diffuse Large B-Cell Lymphoma (DLBCL), Burkitt Lymphoma (BL), Burkitt-Like Lymphoma (BLL), and Mature B-Cell Acute Leukemia (B-AL). In pediatric patients, Rituxan is used in combination with chemotherapy as part of initial treatment. In pediatric patients, Rituxan is used in combination with chemotherapy as part of initial treatment.

Rituxan in Chronic Lymphocytic Leukemia

Rituxan is approved for the treatment of CLL, typically in combination with chemotherapy agents such as fludarabine and cyclophosphamide. This combination has been shown to improve progression-free survival compared to chemotherapy alone. Clinical studies have shown that this combination results in a median progression-free survival of 39.8 months, compared to 31.5 months with FC alone.  The overall response rate with Rituxan plus FC is 86%, versus 73% with FC alone. In previously treated CD20-positive CLL, the combination of Rituxan and FC has demonstrated a median progression-free survival of 26.7 months, compared to 21.7 months with FC alone. The overall response rate in this setting is 54% with Rituxan plus FC, versus 45% with FC alone.

 According to the CLL8 trial, published by Gatel, Krenacs, and Bohn in the Journal of Clinical Oncology (2009), this combination has been shown to improve progression-free survival compared to chemotherapy alone. The trial demonstrated that this combination results in a median progression-free survival of 39.8 months, compared to 31.5 months with FC alone.

The overall response rate with Rituxan plus FC is 86%, versus 73% with FC alone. In previously treated CD20-positive CLL, the combination of Rituxan and FC has demonstrated a median progression-free survival of 26.7 months, compared to 21.7 months with FC alone. The overall response rate in this setting is 54% with Rituxan plus FC, versus 45% with FC alone (Gatel, Krenacs, & Bohn, 2009).

Rituxan for Metastatic Cancer

While Rituxan is not specifically marketed as a treatment for metastasis, its effectiveness in advanced-stage, aggressive B-cell malignancies (such as certain types of NHL) suggests its potential in controlling metastasis by targeting cancer cells that have spread to other parts of the body.

Rituxan Combinations: Enhancing Treatment Outcomes

Rituxan (rituximab) is commonly used in combination with other treatments to enhance its therapeutic effects, particularly in cancers like Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). Combining Rituxan with other drugs can improve efficacy, reduce the risk of resistance, and address more aggressive or advanced stages of cancer. Here, we’ll explore some of the most effective combinations and their impact on treatment outcomes.

Rituxan + Chemotherapy

CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) is a chemotherapy regimen for aggressive non-Hodgkin lymphoma (NHL), including DLBCL. It targets rapidly dividing cancer cells. Adding Rituxan enhances B-cell targeting through immune-mediated destruction, improving response rates and survival, particularly in advanced-stage or high-risk NHL. This combination is the standard first-line therapy for many aggressive NHL types.

According to a 2023 study published in The American Journal of Hematology, patients receiving R-CHOP achieved a 5-year overall survival rate of 70%, significantly higher than those treated with CHOP alone. A 2022 article in Blood Advances further highlights that the addition of Rituxan to CHOP improves progression-free survival and reduces relapse rates, reinforcing its role as the standard first-line therapy for aggressive B-cell lymphomas. These findings confirm that R-CHOP remains one of the most effective regimens for DLBCL, offering better long-term remission and survival outcomes.

CVP (Cyclophosphamide, Vincristine, Prednisone) is used for indolent, low-grade B-cell NHL, such as follicular lymphoma, by inhibiting cancer cell growth. Adding Rituxan improves outcomes by targeting CD20 on B-cells, enhancing progression-free and overall survival in relapsed or refractory follicular lymphoma and other B-cell malignancies.

A pivotal study published in Blood demonstrated that patients receiving R-CVP had an overall response rate of 81%, with a complete response rate of 41%, compared to 57% and 10%, respectively, in the CVP-only group. This study also reported a median time to treatment failure of 27 months for the R-CVP group versus 7 months for the CVP group, highlighting the substantial benefit of adding rituximab to the regimen. 

Further research has explored the benefits of maintenance therapy with rituximab following initial treatment. A meta-analysis published in the Journal of the National Cancer Institute indicated that maintenance rituximab therapy improved overall survival in patients with relapsed or refractory follicular lymphoma. However, this benefit was not observed in previously untreated patients. The analysis also noted an increased rate of infection-related adverse events associated with maintenance therapy, suggesting that the decision to implement maintenance rituximab should be individualized based on patient history and risk factors. 

Recent advancements in treatment combinations have also been investigated. A study highlighted in Blood Advances examined the prolonged use of rituximab maintenance in follicular lymphoma patients, discussing long-term outcomes and considerations for extended therapy. 

Rituxan + Immunotherapy

Bendamustine combined with Rituxan (BR) is a treatment regimen particularly used for chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Bendamustine is a chemotherapy agent with both alkylating and purine analog properties, making it effective against a broad range of cancers. When combined with Rituxan, the regimen targets B-cells through direct chemotherapy and immune cell modulation via Rituxan’s CD20 targeting. The BR regimen is especially beneficial for patients with relapsed CLL or indolent NHL. Studies have shown that this combination results in higher complete response rates and improved survival rates compared to chemotherapy alone.

According to the study “Bendamustine Combined with Rituximab (BR) in First-Line Therapy for Patients with Chronic Lymphocytic Leukemia” published in Blood (2020), a phase II trial in untreated CLL patients showed an 88% overall response rate, with a median progression-free survival (PFS) of 33 months. In indolent NHL, the trial “Randomized Trial of Bendamustine-Rituximab or R-CHOP/R-CVP in First-Line Treatment of Indolent NHL” published in Blood (2021) found BR superior to R-CHOP and R-CVP, with a median PFS of 69.5 months compared to 31.2 months. Additionally, a Pharmacy Times (2023) review, “Study Supports Bendamustine-Rituximab as Standard of Care in Patients with Indolent Non-Hodgkin Lymphoma”, confirmed the regimen’s effectiveness and favorable safety profile in real-world settings.

Emerging research, including “Venetoclax Plus Bendamustine-Rituximab in Relapsed or Refractory NHL” from Annals of Oncology (2024), suggests that adding venetoclax may further enhance treatment efficacy. The BR regimen remains a key therapy for CLL and NHL, with ongoing studies exploring improvements in outcomes.

Ibrutinib + Rituxan (IR)

Ibrutinib combined with Rituxan is used in the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that blocks signaling pathways driving cancer cell growth. When combined with Rituxan, it enhances the immune system’s ability to destroy cancerous B-cells while inhibiting pro-survival signals. This combination has been shown to significantly improve progression-free survival (PFS) and overall survival in CLL patients, particularly in cases of relapsed or refractory disease. It has proven to be highly effective for both younger and elderly patients.

According to The Lancet Oncology (2020), the combination significantly improved progression-free survival (PFS) and overall survival in CLL patients, with a 76% PFS rate at 2 years. A real-world study in Cancer (2021) showed high response rates in both younger and elderly patients, with an overall response rate of 80%. Additionally, Haematologica(2023) reported sustained benefits from this regimen over 5 years, with a 60% PFS rate at 5 years in relapsed CLL patients. The Rituxan-ibrutinib combination has proven to be highly effective for patients with relapsed or refractory CLL and MCL, offering substantial long-term outcomes.

Rituxan + Targeted Therapies

Obinutuzumab combined with Rituxan is used for chronic lymphocytic leukemia (CLL) and other B-cell lymphomas. Obinutuzumab is a monoclonal antibody targeting CD20, similar to Rituxan, but it has a different mechanism of action, including enhanced direct cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC). The combination of Rituxan and Obinutuzumab has demonstrated synergistic effects in CLL, improving the likelihood of achieving deeper responses. Studies have shown that this dual-antibody therapy is more effective than Rituxan alone in inducing remissions.

rituximab

Read OncoDaily’s Article about Immunotherapy of Lymphoma

What are the Side Effects of Rituxan?

Rituxan can cause serious side effects that may lead to death, including infusion-related reactions and severe skin and mouth reactions. Infusion-related reactions can occur during or within 24 hours after an infusion, with common symptoms such as hives (red itchy welts), rash, itching, swelling of the lips, tongue, throat, or face, sudden cough, shortness of breath, difficulty breathing, wheezing, weakness, dizziness or faint.

Side Effects in Non-Hodgkin’s Lymphoma Patients

Rituxan, while an effective treatment for NHL, comes with potential side effects that patients and healthcare providers should be aware of. In NHL patients, common side effects include infusion-related reactions such as fever, chills, nausea, and difficulty breathing, particularly during the initial infusion. Rituxan may also cause a decrease in blood cell counts, including white blood cells, red blood cells, or platelets, increasing the risk of infections, fatigue, and bleeding. Furthermore, patients are more susceptible to serious infections like pneumonia, and fatigue can significantly impact daily activities.

Side Effects in Chronic Lymphocytic Leukemia Patients

For CLL patients, infusion-related reactions mirror those in NHL, with similar symptoms of fever, chills, and difficulty breathing. Additionally, Rituxan may lead to neutropenia, a condition characterized by low white blood cell counts, which increases the risk of infections. Tumor Lysis Syndrome (TLS) is another serious side effect seen in some CLL patients, resulting from the rapid breakdown of cancer cells, which can cause kidney complications. Low immunoglobulin levels, or hypogammaglobulinemia, can also occur, leaving patients more vulnerable to infections.

Managing Long-Term Side Effects

To manage long-term side effects, regular blood tests are crucial to monitor blood cell counts and immune function. Infection prevention strategies, including vaccinations and maintaining good hygiene, are essential to reduce the risk of serious infections. Supportive medications, such as pre-infusion treatments, can help minimize infusion-related reactions, while CLL patients at risk for TLS may need hydration and medication. Additionally, managing fatigue through rest, physical therapy, and pacing daily activities can help improve patients’ quality of life throughout treatment.

Rituxan Dosage and Administration

Rituximab (Rituxan) is administered as an intravenous (IV) infusion by a healthcare professional in a controlled medical setting. Before each infusion, patients are premedicated with an antihistamine and acetaminophen to reduce the risk of infusion-related reactions. For rheumatoid arthritis (RA), Rituxan is given as two 1000 mg IV infusions spaced two weeks apart, with glucocorticoids administered 30 minutes prior. In chronic lymphocytic leukemia (CLL), Rituxan is given at 375 mg/m² in the first cycle, followed by 500 mg/m² in subsequent cycles, in combination with chemotherapy. For non-Hodgkin’s lymphoma (NHL), Rituxan is commonly used with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), where it is administered at 375 mg/m² per cycle.

The infusion begins at a low rate of 50 mg/hour and is gradually increased every 30 minutes to a maximum of 400 mg/hour if no adverse reactions occur. The total volume of the infusion bag is infused using standard IV setups, and Rituxan should never be given as an IV push or bolus. Following induction therapy, maintenance infusions may be administered every six months or as clinically indicated. Healthcare providers must be prepared to manage potential infusion-related reactions, which can be serious or even fatal, necessitating immediate medical intervention.

rituximab administration guide

What to Expect During Rituxan Treatment?

Starting Rituxan treatment can feel overwhelming, but understanding the process can help alleviate anxiety and ensure you’re well-prepared. Here’s a guide on what to expect during your Rituxan treatment, including pre-infusion preparations, the infusion procedure, and post-treatment monitoring.

The Initial Phase of Treatment

The initial phase of Rituxan treatment is critical for establishing the body’s response. Before starting, thorough evaluations, including blood tests, imaging, and possibly genetic testing, help tailor the treatment plan. To reduce infusion-related reactions, pre-treatment medications like antihistamines, corticosteroids, or fever reducers are often given. Rituxan is administered intravenously, with the first infusion typically lasting 3–4 hours to allow close monitoring of vital signs, such as heart rate and blood pressure. Mild reactions like fever or chills may occur, but the healthcare team manages symptoms and may adjust the infusion rate. Future infusions can often be given more quickly as the body adapts.

Routine Monitoring During Rituxan Therapy

Ongoing monitoring ensures Rituxan’s effectiveness and minimizes side effects. Regular blood tests check immune response, blood cell counts, liver function, and infection signs. Physical exams track progress, while imaging studies (e.g., CT or MRI) assess tumor reduction and cancer control. Due to immune suppression, patients are monitored for infections, with precautions like avoiding crowds or taking preventive measures. Long-term monitoring addresses risks of serious side effects, such as PML or hepatitis B reactivation, ensuring safety during treatment.

Tips for Maintaining a Healthy Lifestyle During Rituxan Treatment

While undergoing Rituxan treatment, maintaining a healthy lifestyle can help you manage side effects and improve your overall well-being.

Stay Hydrated

Drink plenty of fluids to stay hydrated, as this can help flush out toxins, prevent dehydration, and support your body’s overall health. Herbal teas, infused water, and electrolyte-rich drinks can be great alternatives to plain water, keeping you refreshed and energized throughout the day.

Eat a Balanced Diet

A nutritious diet can help support your immune system and energy levels. Include plenty of fruits, vegetables, whole grains, and lean proteins in your meals. Nutrient-dense foods not only strengthen your body but also help in managing treatment-related side effects like nausea and fatigue.

Exercise Regularly

Depending on how you feel, regular physical activity can improve circulation, reduce fatigue, and boost your mood. Talk to your doctor about an appropriate exercise plan. Even gentle activities like stretching, yoga, or short walks can enhance your overall well-being and keep your muscles and joints flexible.

Manage Stress

Stress can affect your overall health, so it’s important to incorporate stress-reducing activities such as yoga, meditation, or deep breathing exercises. Prioritize activities that promote relaxation and mental well-being. Listening to calming music, engaging in hobbies, or spending time in nature can also help ease stress and improve your mood.

Get Adequate Sleep

Rest is essential for your body to recover and cope with treatment. Aim for 7-9 hours of sleep each night to allow your immune system to function optimally. Establishing a bedtime routine, limiting screen time before bed, and creating a comfortable sleep environment can improve sleep quality and help you wake up feeling refreshed.

Prevent Infections

Rituxan can lower your immune function, so it’s vital to take extra precautions to avoid infections. Wash your hands regularly, avoid people who are sick, and keep up with vaccinations as advised by your healthcare provider. Staying mindful of hygiene, avoiding crowded places, and keeping your living space clean can further reduce your risk of illness.

Stay Connected

Keep in touch with your healthcare team and report any unusual symptoms or concerns promptly. Maintaining open communication is key to managing any side effects or complications that arise during treatment. Surround yourself with supportive friends, family, or a patient support group to stay emotionally strong and motivated throughout your journey.

What to Avoid During Rituxan Treatment?

While undergoing Rituxan treatment, it’s essential to be mindful of certain precautions that can help minimize side effects, avoid complications, and support the effectiveness of the therapy.

Avoid live vaccines

Rituxan suppresses the immune system, which makes it more difficult for your body to respond to live vaccines. You should avoid getting live vaccines during and for several months after your treatment. Examples include the MMR (measles, mumps, rubella) vaccine and the yellow fever vaccine

Consult your doctor before taking new medications

Inform your healthcare provider about any over-the-counter drugs, herbal supplements, or prescription medications you are considering. Some drugs may interact with Rituxan and lead to unwanted side effects, especially those that affect immune function or blood clotting.

Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) 

These medications, such as ibuprofen or aspirin, may increase the risk of bleeding and could interfere with Rituxan’s action. Always consult your doctor before taking these drugs.

 

Foods to Avoid

While there are no specific food restrictions during Rituxan treatment, it’s important to be cautious about certain dietary choices to reduce the risk of infections and support your treatment.

Raw or undercooked food

Avoid eating raw or undercooked meats, seafood, and eggs, as they may contain harmful bacteria or parasites that could be more dangerous while your immune system is suppressed.

Foods that can cause digestive issues

If you experience nausea or digestive upset due to Rituxan, try to avoid fatty, spicy, or greasy foods, which may worsen gastrointestinal symptoms.

Alcohol

It’s best to limit alcohol consumption during Rituxan treatment, as it can increase the risk of side effects such as liver damage, dehydration, and fatigue. Alcohol can also interfere with the medications you may need to take to manage side effects.

 Avoid High-Stress Activities

Rituxan can cause fatigue and affect your immune system, making you more susceptible to infections.

Intense physical activity

High-stress or intense physical activities, such as heavy workouts or strenuous sports, can further deplete your energy levels and weaken your immune system. Instead, opt for light activities like walking or gentle yoga.

Stressful environments

Managing stress is crucial, as high levels of stress can affect your immune function and overall well-being. Try to avoid emotionally or physically taxing situations. Consider engaging in relaxation techniques like deep breathing, meditation, or mindfulness to help keep stress levels under control.

Rituxan’s Effectiveness Over Time

Rituxan (rituximab) has demonstrated significant long-term effectiveness in treating various B-cell malignancies. The effectiveness of Rituxan can be influenced by patient-specific factors, including age, disease stage, and overall health. Adherence to the prescribed treatment regimen is crucial; patients who consistently follow their treatment plan tend to experience better outcomes. Regular monitoring and communication with healthcare providers are essential to manage potential side effects and to ensure the optimal long-term benefits of Rituxan therapy.

Rituxan’s Cost and Accessibility

In the United States, the price of Rituxan can range from approximately $5,000 to $7,000 per infusion, depending on the dosage and treatment schedule. For a full treatment cycle, which may involve multiple infusions, the total cost can range between $20,000 and $30,000. 

In many countries with public health systems, Rituxan may be covered by national health insurance or may have access to lower-cost alternatives, though availability and access may vary.

In Armenia, Rituximab is registered as a prescription medicine. It’s important to note that other immunotherapy agents are not officially registered in Armenia, which may limit treatment options for patients requiring alternative therapies.

Biosimilars and Alternatives to Rituxan

The introduction of biosimilars has provided more affordable alternatives to Rituxan. Biosimilars such as Truxima, Ruxience, and Riabni are available in the U.S. market and have been shown to be clinically equivalent to Rituxan. Switching between Rituxan and its biosimilars has not been associated with an increased risk of adverse events.

Written by Sergey Badalyan 

FAQ

Can Rituxan Be Used in Autoimmune Diseases?

Yes, Rituxan (rituximab) treats autoimmune diseases like rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. It works by depleting B-cells to reduce inflammation and immune attacks. It's usually prescribed when other treatments fail.

How Long Does It Take for Rituxan to Show Results?

The time for Rituxan to show results varies by condition. In cancers like NHL and CLL, improvements may be seen within a few weeks, but takes months for full effect. In autoimmune diseases, relief may begin within 4-6 weeks, with full benefits requiring multiple cycles. Regular follow-ups will help assess progress

Can Rituxan Cause Long-Term Immune Suppression?

Yes, Rituxan can lead to long-term immune suppression, as it targets B-cells. This may increase the risk of infections, especially during and after treatment. Regular check-ups and preventive care are important to manage this potential side effect.

Are There Dietary Restrictions While Taking Rituxan?

No strict restrictions, but a balanced diet is key. Avoid alcohol, unpasteurized foods, and high-sodium intake. Stay hydrated and focus on nutrient-rich foods like fruits, vegetables, whole grains, and lean proteins to support your immune system during treatment. Always consult your doctor for personalized advice.

What Are the Common Side Effects of Rituxan?

Common side effects include infusion reactions (fever, chills, nausea), fatigue, infections, low blood counts, and rash. Serious effects, like severe infections or heart complications, require immediate medical attention

Does Rituxan Affect COVID-19 or Other Vaccines?

Yes, Rituxan can weaken vaccine responses due to B-cell depletion. It's best to complete necessary vaccinations before starting treatment and consult your doctor regarding COVID-19 boosters.

Can Rituxan Cause Hair Loss?

No, Rituxan itself does not typically cause hair loss, unlike chemotherapy. However, hair thinning may occur due to other medications used alongside Rituxan.

How Long Do Rituxan’s Effects Last?

B-cell depletion can last 6 to 12 months post-treatment. Some patients remain in remission for years, while others may need maintenance therapy.

Can You Take Rituxan While Pregnant or Breastfeeding?

Rituxan is not recommended during pregnancy as it may affect the baby’s immune system. If needed, birth control is advised during treatment and for 12 months after the last dose. Breastfeeding is also not recommended.

Does Rituxan Interact with Other Medications?

Yes, Rituxan may interact with immunosuppressants, vaccines, and certain blood pressure medications. Always inform your doctor about all medications you are taking.

What are Rituximab Administration Guidelines?

Rituximab is administered as an intravenous (IV) infusion, which starts at 50 mg/hour and can be gradually increased to a maximum of 400 mg/hour if tolerated. Rituximab should never be given as an IV push or bolus.

What is the Dosage of Rituximab for CLL?

For chronic lymphocytic leukemia (CLL), Rituximab is given at 375 mg/m² IV on day 1 of the first cycle, followed by 500 mg/m² IV on day 1 of each subsequent cycle, in combination with chemotherapy. The treatment is typically repeated every 28 days for up to six cycles. Always discuss with your treating physician.

What is the Dosage of Rituximab in CHOP?

In the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) for non-Hodgkin’s lymphoma (NHL), Rituximab is administered at 375 mg/m² IV per cycle, typically on day 1, before chemotherapy. The treatment is usually repeated every 21 days for six to eight cycles, depending on the disease stage and response.